Literature DB >> 22085556

New insights in mucosal vaccine development.

Vincent Pavot1, Nicolas Rochereau, Christian Genin, Bernard Verrier, Stéphane Paul.   

Abstract

Mucosal surfaces are the major entrance for infectious pathogens and therefore mucosal immune responses serve as a first line of defence. Most current immunization procedures are obtained by parenteral injection and only few vaccines are administered by mucosal route, because of its low efficiency. However, targeting of mucosal compartments to induce protective immunity at both mucosal sites and systemic level represents a great challenge. Major efforts are made to develop new mucosal candidate vaccines by selecting appropriate antigens with high immunogenicity, designing new mucosal routes of administration and selecting immune-stimulatory adjuvant molecules. The aim of mucosal vaccines is to induce broad potent protective immunity by specific neutralizing antibodies at mucosal surfaces and by induction of cellular immunity. Moreover, an efficient mucosal vaccine would make immunization procedures easier and be better suited for mass administration. This review focuses on contemporary developments of mucosal vaccination approaches using different routes of administration.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 22085556     DOI: 10.1016/j.vaccine.2011.11.003

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  69 in total

Review 1.  Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.

Authors:  Mevyn Nizard; Mariana O Diniz; Helene Roussel; Thi Tran; Luis Cs Ferreira; Cecile Badoual; Eric Tartour
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

Review 3.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

4.  Immunologic Pathways in Protective versus Maladaptive Host Responses to Attenuated and Pathogenic Strains of Mycoplasma gallisepticum.

Authors:  Jessica Beaudet; Edan R Tulman; Katherine Pflaum; Jessica A Canter; Lawrence K Silbart; Steven J Geary
Journal:  Infect Immun       Date:  2019-02-21       Impact factor: 3.441

5.  From allergen to oral vaccine carrier: A new face of ragweed pollen.

Authors:  Md Jasim Uddin; Harvinder Singh Gill
Journal:  Int J Pharm       Date:  2018-05-03       Impact factor: 5.875

Review 6.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

Review 7.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2013-08-19       Impact factor: 4.939

9.  Optimization of immune strategy for a construct of Salmonella-delivered ApxIA, ApxIIA, ApxIIIA and OmpA antigens of Actinobacillus pleuropneumoniae for prevention of porcine pleuropneumonia using a murine model.

Authors:  Jin Hur; John Hwa Lee
Journal:  Vet Res Commun       Date:  2013-12-05       Impact factor: 2.459

Review 10.  Activation of B cells by a dendritic cell-targeted oral vaccine.

Authors:  Bikash Sahay; Jennifer L Owen; Tao Yang; Mojgan Zadeh; Yaima L Lightfoot; Jun-Wei Ge; Mansour Mohamadzadeh
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.